Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Black Raspberries in MDS/MPN
NCT03140280Phase 2Completed
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN). Primary endpoint: The Number of Patients With Grade 3 or Higher Serious Adverse Events at 52 weeks. Started Jun 2017; status: completed.
02
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT03140280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03140280.